보고서 요약(국문)

개요
전 세계 두경부 편평세포암 시장은 2022년 22억 달러 규모에 달했으며, 2023년부터 2030년까지 연평균 8.8%의 성장률을 기록하며 2030년에는 43억 달러에 이를 것으로 예상됩니다. 두경부 편평세포암 시장은 발병률 및 유병률 증가, 연구 발전, 연구 개발 활동 확대, 정부 정책 지원 등의 요인에 의해 성장하고 있습니다.
두경부 편평세포암은 입, 목, 비강을 포함한 두경부 점막 표면을 덮고 있는 편평세포에서 발생합니다. 두경부 편평세포암 시장은 보조 치료, 연구, 치료 등 광범위한 분야를 포괄합니다. 치료 방법에는 수술, 방사선 치료, 화학 요법, 표적 치료, 면역 요법 등이 포함됩니다.

시장 동향
연구 활동 증가가 전 세계 두경부 편평세포암 시장 성장을 견인하고 있습니다.
예를 들어, 글로벌 생명공학 기업 라쿠텐 메디컬(Rakuten Medical, Inc.)은 자사의 독자적인 알루미녹스(Alluminox™) 플랫폼을 기반으로 정밀 세포 표적 치료제를 개발 및 판매하고 있으며, 2023년 7월 10일 미국 두경부학회(AHNS) 제11회 국제 두경부암 학술대회(AHNS 2023)에서 ASP-1929-181 연구의 새로운 데이터가 발표되었다고 밝혔습니다.
ASP-1929-181 연구에 참여한 국소 및/또는 전이성 두경부 편평세포암(HNSCC) 환자 19명을 대상으로 한 예비 분석 결과, ASP-1929와 항PD-1 치료제를 병용한 알루미녹스 치료의 새로운 치료 전략이 환자들에게 고무적인 초기 결과를 보였습니다.
두경부암은 PD-1 치료제로 치료되는 종양 유형 중 하나입니다. 본 연구의 예비 결과는 재발성 두경부암에 대한 새롭고 획기적인 치료법으로서의 잠재력을 평가하기 위한 추가 연구의 필요성을 시사합니다. 항종양 면역 반응은 EGFR+ 종양과 PD-1 차단을 모두 표적으로 할 경우, 각각의 치료법 단독보다 지속적인 종양 크기 감소를 유도할 것으로 예상됩니다.
주요 기업들이 전 세계 두경부 편평세포암 시장 성장을 주도하고 있습니다.
예를 들어, 2023년 6월, 중국 및 기타 주요 아시아 시장에서 환자들에게 획기적인 의약품을 제공하는 데 전념하는 생명공학 기업인 리안바이오(LianBio)와 암 환자를 위한 치료 옵션 확대를 위해 물리 기반 접근법을 개척하는 후기 임상 단계 생명공학 기업인 나노바이오틱스(NANOBIOTIX)는 백금 기반 화학요법을 받을 수 없는 국소 진행성 두경부 편평세포암(LA-HNSCC)을 앓는 고령 환자 치료를 위한 NBTXR3의 효능을 평가하는 글로벌 3상 등록 임상시험인 나노레이-312(NANORAY-312)에 아시아 최초 환자를 무작위 배정했다고 발표했습니다.

고위험군이며 화학요법을 받을 수 없는 고령의 국소 진행성 두경부암 환자를 대상으로 하는 NANORAY-312는 방사선 활성화 NBTXR3(세툭시맙 병용 또는 비병용)와 방사선 치료(세툭시맙 병용 또는 비병용)의 효과 및 안전성을 비교하는 것을 목표로 하는 글로벌 2군 무작위 배정, 연구자 선택 3상 임상 등록 연구입니다.
두경부 편평세포암 치료와 관련된 부작용이 시장 성장을 저해하고 있습니다.
두경부 편평세포암 약물 치료와 관련된 부작용은 시장 성장을 제한하는 요인입니다. 화학요법의 부작용으로는 구토 및 메스꺼움, 피로, 탈모, 혈구 수 감소로 인한 출혈 위험 증가, 빈혈, 감염, 구내염 및 염증, 식욕 부진, 변비 또는 설사 등이 있습니다.

표적 치료의 부작용으로는 발진과 같은 피부 반응, 설사와 같은 위장 문제, 피로, 혈압 상승, 간 기능 변화, 혈전 또는 출혈 위험 증가, 관절 또는 근육통 등이 있습니다.
면역 요법의 부작용으로는 피로, 피부 반응(발진, 가려움), 독감 증상(발열, 오한, 몸살 등), 기침, 호흡 곤란, 설사 또는 대장염, 내분비계 관련 부작용(호르몬 불균형, 갑상선 기능 장애) 등이 있습니다.
세분화 분석
전 세계 두경부 편평세포암 시장은 유형, 약물 종류, 투여 경로, 치료법, 최종 사용자 및 지역별로 세분화됩니다.

방사선 치료 부문은 예측 기간 동안 시장에서 지배적인 위치를 유지할 것으로 예상됩니다.
방사선 치료 부문은 2022년 두경부 편평세포암 시장에서 약 45.4%의 가장 높은 시장 점유율을 차지했습니다. 권장 치료법은 1일, 22일, 43일에 방사선 치료(RT)와 병행하여 고용량 시스플라틴 100mg/m2를 투여하는 것입니다. 이 치료법은 독성이 상당히 높기 때문에 효능은 동일하지만 독성이 낮은 대체 화학 요법이 선호됩니다.
최근, 전향적 무작위 2/3상 JCOG1008 연구에서는 수술 후 항암방사선 치료를 계획한 고위험 아시아 LA-HNSCC 환자 261명을 대상으로 3주마다 투여하는 시스플라틴 100mg/m2와 매주 투여하는 시스플라틴 40mg/m2의 효과와 안전성을 비교했습니다. 주 1회 시스플라틴 투여는 중앙값 추적 관찰 기간 2.2년 후 3년 시점에서 주요 평가 지표인 전체 생존율(OS) 측면에서 비열등한 것으로 나타났습니다.
지역별 시장 점유율
북미, 세계 두경부 편평세포암 시장에서 지배적인 위치 차지
북미는 2023년 전체 시장 점유율의 약 39.7%를 차지할 것으로 추정됩니다. 주요 기업들이 북미 지역 시장 성장을 주도하고 있습니다. 예를 들어, 2022년 7월 플리안트(Pliant)는 경구용 이중 선택적 vβ6/vβ1 인테그린 억제제인 PLN-74809가 미국 식품의약국(FDA)으로부터 두경부 편평세포암(PSC) 치료 가능성에 대해 신속 심사(Fast Track) 지정을 받았다고 발표했습니다.

당사의 핵심 치료 후보 물질인 PLN-74809는 INTEGRIS-PSC 2a상 임상 시험(NCT04480840)에서 평가되고 있습니다. PSC 환자를 대상으로 하는 이 무작위 배정, 이중 맹검, 위약 대조 임상 시험의 주요 결과는 2023년 상반기에 발표될 예정입니다. 따라서 이러한 요소들은 해당 지역 시장 확장을 뒷받침합니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Sanofi, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH., GSK plc, Novartis AG, Bayer AG, Merck & Co., Inc., AstraZeneca, Eli Lilly and Co., Cipla Inc. 등이 있습니다.

COVID-19 영향 분석
러시아-우크라이나 분쟁 분석
러시아-우크라이나 전쟁은 지정학적 불안정과 경제적 불확실성으로 인해 의료 시설 부족을 초래하여 두경부 편평세포암 시장에 영향을 미칠 수 있습니다. 분쟁의 직접적인 영향을 받는 지역에서는 의료 지식 및 의료 시설 접근성이 저해될 수 있습니다. 이는 효율적이고 시의적절한 두경부 편평세포암 치료 제공 능력에 영향을 줄 수 있습니다.
러시아 또는 우크라이나가 두경부 편평세포암 연구 및 개발에 상당한 기여를 하고 있는 경우, 분쟁으로 인해 진행 중인 연구 및 임상 시험이 방해받아 새롭고 더 효과적인 치료법의 출시가 지연될 수 있습니다.
인공지능 분석:
인공지능(AI)은 데이터 분석의 다양한 측면을 개선하기 위해 두경부 편평세포암 시장에서 점점 더 많이 사용되고 있습니다. 새로운 치료 분자를 발굴하고 두경부 편평세포암에 대한 효과를 예측하기 위해 AI가 신약 개발 과정에 활용됩니다. AI는 분자 상호작용을 모방하고 새로운 약물과 암세포 간의 잠재적 상호작용을 예측할 수 있습니다.

CT 스캔, MRI, PET 스캔 등의 의료 영상 데이터는 AI 알고리즘을 통해 분석되어 두경부암(HNSCC)을 암시하는 미세한 패턴과 이상 징후를 찾아낼 수 있습니다. 이는 정확한 진단과 조기 발견에 도움을 주어 신속한 치료를 가능하게 합니다.
유형별
• 타액선
• 구강 및 구인두
• 비강 및 부비동
• 비인두
• 후두
• 하인두
약물 계열별
• EGFR 억제제
• 면역 체크포인트 억제제
• 기타
투여 경로별
• 정맥 주사
• 경구 투여
• 기타
치료 방법별
• 방사선 치료
• 화학 요법
• 면역 요법
최종 사용자별
• 병원
• 전문 클리닉
• 외래 수술 센터
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
• 아시아 태평양 지역 (기타)
• 중동 및 아프리카
주요 개발 동향
• 2022년 12월, 암 환자를 위한 물리 기반 치료 접근법을 개척해 온 임상 후기 단계 생명공학 기업 나노바이오틱스(NANOBIOTIX)는 백금 기반 항암화학요법을 받을 수 없는 고령의 국소 진행성 두경부 편평세포암(LA-HNSCC) 환자 치료를 위한 NBTXR3의 효능을 평가하는 글로벌 3상 임상시험인 나노레이-312(NANORAY-312)에 미국 내 첫 환자가 무작위 배정되었다고 발표했습니다.
보고서 구매 이유

• 유형, 약물 계열, 투여 경로, 치료법, 최종 사용자 및 지역별 글로벌 두경부 편평세포암 시장 세분화를 시각화하고 주요 상업적 자산과 기업을 파악하기 위함입니다.

• 트렌드 및 공동 개발 분석을 통해 상업적 기회를 식별하기 위함입니다.

• 모든 세그먼트를 포함한 두경부 편평세포암 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공.
글로벌 두경부 편평세포암 시장 보고서는 약 69개의 표, 72개의 그림, 195페이지 분량으로 구성됩니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Head and Neck Squamous Cell Carcinoma Market reached US$ 2.2 billion in 2022 and is expected to reach US$ 4.3 billion by 2030 growing with a CAGR of 8.8% during the forecast period 2023-2030. The head and neck squamous cell carcinoma market is driven by factors such as increasing incidence and prevalence, advancements in research, increased research and development activities, and government initiatives.
Squamous cells that line the mucosal surfaces of the head and neck region, including the mouth, throat, and nasal passages, are where head and neck squamous cell carcinoma develops. The HNSCC market covers a wide range of topics, including supportive care, research, and therapy. It includes a variety of therapeutic methods, including operations, radiation, chemotherapy, targeted therapy, and immunotherapy.
Market Dynamics
The Increasing Research Activities are Driving the Global Head and Neck Squamous Cell Carcinoma Market Growth
For instance, on July 10, 2023, new data from the ASP-1929-181 study was presented at the American Head and Neck Society's (AHNS) 11th International Conference on Head and Neck Cancer (AHNS 2023), according to Rakuten Medical, Inc., a global biotechnology company developing and marketing precision, cell targeting therapies based on its proprietary AlluminoxTM platform.
The preliminary analysis of 19 patients with locoregional and/or metastatic head and neck squamous cell carcinoma (HNSCC) who were enrolled in the ASP-1929-181 study suggested that the novel treatment strategy of Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy showed encouraging early results in patients.
Head and neck cancers are among the tumor types that are treated with PD-1 treatment. The preliminary findings of this study call for further investigation to assess its potential as a novel, cutting-edge therapy for recurrent head and neck cancer. The antitumor immune response is projected to lead to enhanced tumor-shrinking that is lasting compared to either treatment alone when targeting both EGFR+ tumors and PD-1 blocking.
The Active Major Players are Driving the Global Head and Neck Squamous Cell Carcinoma Market Growth
For instance, in June 2023, LianBio, a biotechnology company committed to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and NANOBIOTIX, a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment options for cancer patients, announced the randomization of the first patient in Asia in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced cancer and neck squamous cell carcinoma (“LA-HNSCC”) who are ineligible for platinum-based chemotherapy.
In high-risk, chemotherapy-ineligible elderly patients with LA, NANORAY-312 is a global, two-arm, randomized, Investigator's Choice Phase 3 registrational study that aims to compare the effectiveness and safety of radiotherapy-activated NBTXR3 with or without cetuximab to radiotherapy with or without cetuximab.-HNSCC.
Side Effects Associated with Head and Neck Squamous Cell Carcinoma Therapy are Hampering the Market Growth
Side effects associated with head and neck squamous cell carcinoma medication therapy restraining the market growth. Chemotherapy’s side effects include vomiting and nauseous, Fatigue, loss of hair lowered blood cell counts, which raises the risk of bleeding, anemia, infection mouth ulcers, and sores decrease in appetite, constipation, or diarrhea.
Targeted Treatment side effects include skin responses, such as rashes, gastrointestinal issues like diarrhea Fatigue, elevated blood pressure alterations in liver function, and increased chance of clotting or bleeding joint or muscle aches.
Immunotherapy Fatigue, responses on the skin (rash, itching), signs of the flu (such as fever, chills, and body aches), coughing, breathlessness, either diarrhea or colitis adverse effects relating to the endocrine system (hormone imbalances, thyroid malfunction).
Segment Analysis
The global head and neck squamous cell carcinoma market is segmented based on type, drug class, route of administration, treatment, end-user and region.
The Radiotherapy Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period
The radiotherapy segment accounted for the highest market stake accounting for approximately 45.4% of the head and neck squamous cell carcinoma market in 2022. The recommended course of treatment is high-dose cisplatin 100 mg/m2 administered concurrently with radiotherapy (RT) on days 1, 22, and 43. Alternative chemotherapy regimens with equivalent efficacy but less toxicity are preferred because this one has significant toxicity.
Recently, the prospective randomized phase II/III JCOG1008 research compared the effectiveness and safety of bolus cisplatin 100 mg/m2 administered every three weeks against weekly cisplatin 40 mg/m2 in 261 high-risk Asian LA-HNSCC patients planned for postoperative chemoradiation. Weekly cisplatin was found to be non-inferior with respect to the main endpoint OS at 3 years after a median follow-up of 2.2 years.
Geographical Penetration
North America Holds a Dominant Position in the Global Head and Neck Squamous Cell Carcinoma Market
North America is estimated to hold around 39.7% of the total market share in 2023. The active major players are driving the market in the North American region. For instance, in July 2022, Pliant stated that PLN-74809, an oral, dual-selective vß6/vß1 integrin inhibitor, has been given Fast Track designation by the U.S. Food and Drug Administration (FDA) for the possible treatment of Head and Neck squamous Cell Carcinoma (PSC).
The core treatment candidate of the Company, PLN-74809, is being evaluated in the INTEGRIS-PSC Phase 2a clinical trial (NCT04480840). In the first half of 2023, topline results from this randomized, double-blind, placebo-controlled trial in PSC patients are anticipated. As a result, the aforementioned elements support market expansion in the region.
Competitive Landscape
The major global players in the market include Sanofi, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH., GSK plc, Novartis AG, Bayer AG, Merck & Co., Inc., AstraZeneca, Eli Lilly and Co, and Cipla Inc. among others.
COVID-19 Impact Analysis
Russia-Ukraine Conflict Analysis
The Russia-Ukraine war may affect the head and neck squamous cell carcinoma market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Access to medical knowledge and healthcare facilities may be hampered in areas that are directly affected by the conflict. This might affect our capacity to deliver efficient and timely HNSCC treatments.
If either Russia or Ukraine makes a substantial contribution to the study and development of HNSCC, the conflict may impede ongoing research and clinical trials, possibly delaying the release of novel and more effective therapies.
Artificial Intelligence Analysis:
Artificial intelligence (AI) is increasingly being used in the head and neck squamous cell carcinoma market to improve various aspects of data analysis. To find new therapeutic molecules and forecast their effectiveness against HNSCC, AI is employed in the drug discovery process. It can mimic molecular interactions and forecast potential interactions between new medications and cancer cells.
Medical imaging data from CT scans, MRIs, and PET scans can be analyzed by AI algorithms to look for minute patterns and anomalies that can point to HNSCC. This can help with accurate diagnosis and early discovery, enabling prompt intervention.
By Type
• Salivary Gland
• Oral and Oropharyngeal
• Nasal Cavity &Paranasal Sinuses
• Nasopharyngeal
• Laryngeal
• Hypo Pharyngeal
By Drug Class
• EGFR Inhibitors
• Immune Checkpoint Inhibitors
• Others
By Route of Administration
• Intravenous
• Oral
• Others
By Treatment
• Radiation
• Chemotherapy
• Immunotherapy
By End-user
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In December 2022, NANOBIOTIX, a late-clinical-stage biotechnology company that has pioneered physics-based approaches to expand treatment options for cancer patients reported that the first patient in the United States has been randomized in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma ("LA-HNSCC") who are ineligible for platinum-based chemotherapy.
Why Purchase the Report?
• To visualize the global head and neck squamous cell carcinoma market segmentation based on the type, drug class, route of administration, treatment, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of head and neck squamous cell carcinoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global head and neck squamous cell carcinoma market report would provide approximately 69 tables, 72 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drug Class
3.3. Snippet by Route of Administration
3.4. Snippet by Treatment
3.5. Snippet by End-user
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising research activities
4.1.2. Restraints
4.1.2.1. Side effects associated with head and neck squamous cell carcinoma
4.1.3. Opportunity
4.1.3.1. Technological advancements
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.1.2. Market Attractiveness Index, By Type
9.2. Salivary Gland *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Oral and Oropharyngeal
9.4. Nasal Cavity &Paranasal Sinuses
9.5. Nasopharyngeal
9.6. Laryngeal
9.7. Hypo Pharyngeal
10. By Drug Class
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.1.2. Market Attractiveness Index, By Drug Class
10.2. EGFR Inhibitors*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Immune Checkpoint Inhibitors
10.4. Others
11. By Route of Administration
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.1.2. Market Attractiveness Index, By Route of Administration
11.2. Intravenous*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Oral
11.4. Others
12. By Treatment
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.1.2. Market Attractiveness Index, By Treatment
12.2. Radiation*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Chemotherapy
12.4. Immunotherapy
13. By End-user
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.1.2. Market Attractiveness Index, By End-user
13.2. Hospitals*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Specialty Clinics
13.4. Ambulatory Surgical Centers
14. By Region
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
14.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.8.1. U.S.
14.2.8.2. Canada
14.2.8.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
14.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.8.1. Germany
14.3.8.2. U.K.
14.3.8.3. France
14.3.8.4. Italy
14.3.8.5. Spain
14.3.8.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
14.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.8.1. Brazil
14.4.8.2. Argentina
14.4.8.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
14.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.8.1. China
14.5.8.2. India
14.5.8.3. Japan
14.5.8.4. Australia
14.5.8.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
14.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
15. Competitive Landscape
15.1. Competitive Scenario
15.2. Product Benchmarking
15.3. Company Share Analysis
15.4. Key Developments and Strategies
16. Company Profiles
16.1.1. Sanofi*
16.1.1.1. Company Overview
16.1.1.2. Product Portfolio and Description
16.1.1.3. Financial Overview
16.1.1.4. Key Developments
16.1.2. F. Hoffmann-La Roche Ltd.
16.1.3. Boehringer Ingelheim International GmbH.
16.1.4. GSK plc
16.1.5. Novartis AG
16.1.6. Bayer AG
16.1.7. Merck & Co., Inc.
16.1.8. AstraZeneca
16.1.9. Eli Lilly and Co
16.1.10. Cipla Inc.
LIST NOT EXHAUSTIVE
17. Appendix
17.1. About Us and Services
17.2. Contact Us

언급된 주요 기업들

1.	Sanofi, 1.4.	Key Developments, 2.	F. Hoffmann-La Roche Ltd., 3.	Boehringer Ingelheim International GmbH., 4.	GSK plc, 5.	Novartis AG, 6.	Bayer AG, 7.	Merck & Co., Inc., 8.	AstraZeneca, 9.	Eli Lilly and Co, 10.	Cipla Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Head and Neck Squamous Cell Carcinoma Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Head and Neck Squamous Cell Carcinoma Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Head and Neck Squamous Cell Carcinoma Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Head and Neck Squamous Cell Carcinoma Market Value, By Treatment, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Head and Neck Squamous Cell Carcinoma Market Value, By End-user , 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Head and Neck Squamous Cell Carcinoma Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 7 Global Head and Neck Squamous Cell Carcinoma Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 8 Global Head and Neck Squamous Cell Carcinoma Market Value, By Type, 2021-2030 (US$ Billion)

Table 9 Global Head and Neck Squamous Cell Carcinoma Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Billion)

Table 10 Global Head and Neck Squamous Cell Carcinoma Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 11 Global Head and Neck Squamous Cell Carcinoma Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 12 Global Head and Neck Squamous Cell Carcinoma Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 13 Global Head and Neck Squamous Cell Carcinoma Market Value, By Treatment, 2022, 2026 & 2030 (US$ Billion)

Table 14 Global Head and Neck Squamous Cell Carcinoma Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 15 Global Head and Neck Squamous Cell Carcinoma Market Value, By End-user , 2022, 2026 & 2030 (US$ Billion)

Table 16 Global Head and Neck Squamous Cell Carcinoma Market Value, By End-user , 2021-2030 (US$ Billion)

Table 17 Global Head and Neck Squamous Cell Carcinoma Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 18 Global Head and Neck Squamous Cell Carcinoma Market Value, By Region, 2021-2030 (US$ Billion)

Table 19 North America Head and Neck Squamous Cell Carcinoma Market Value, By Type, 2021-2030 (US$ Billion)

Table 20 North America Head and Neck Squamous Cell Carcinoma Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 21 North America Head and Neck Squamous Cell Carcinoma Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 22 North America Head and Neck Squamous Cell Carcinoma Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 23 North America Head and Neck Squamous Cell Carcinoma Market Value, By End-user , 2021-2030 (US$ Billion)

Table 24 North America Head and Neck Squamous Cell Carcinoma Market Value, By Country, 2021-2030 (US$ Billion)

Table 25 South America Head and Neck Squamous Cell Carcinoma Market Value, By Type, 2021-2030 (US$ Billion)

Table 26 South America Head and Neck Squamous Cell Carcinoma Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 27 South America Head and Neck Squamous Cell Carcinoma Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 28 South America Head and Neck Squamous Cell Carcinoma Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 29 South America Head and Neck Squamous Cell Carcinoma Market Value, By End-user , 2021-2030 (US$ Billion)

Table 30 South America Head and Neck Squamous Cell Carcinoma Market Value, By Country, 2021-2030 (US$ Billion)

Table 31 Europe Head and Neck Squamous Cell Carcinoma Market Value, By Type, 2021-2030 (US$ Billion)

Table 32 Europe Head and Neck Squamous Cell Carcinoma Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 33 Europe Head and Neck Squamous Cell Carcinoma Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 34 Europe Head and Neck Squamous Cell Carcinoma Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 35 Europe Head and Neck Squamous Cell Carcinoma Market Value, By End-user , 2021-2030 (US$ Billion)

Table 36 Europe Head and Neck Squamous Cell Carcinoma Market Value, By Country, 2021-2030 (US$ Billion)

Table 37 Asia-Pacific Head and Neck Squamous Cell Carcinoma Market Value, By Type, 2021-2030 (US$ Billion)

Table 38 Asia-Pacific Head and Neck Squamous Cell Carcinoma Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 39 Asia-Pacific Head and Neck Squamous Cell Carcinoma Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 40 Asia-Pacific Head and Neck Squamous Cell Carcinoma Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 41 Asia-Pacific Head and Neck Squamous Cell Carcinoma Market Value, By End-user , 2021-2030 (US$ Billion)

Table 42 Asia-Pacific Head and Neck Squamous Cell Carcinoma Market Value, By Country, 2021-2030 (US$ Billion)

Table 43 Middle East & Africa Head and Neck Squamous Cell Carcinoma Market Value, By Type, 2021-2030 (US$ Billion)

Table 44 Middle East & Africa Head and Neck Squamous Cell Carcinoma Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 45 Middle East & Africa Head and Neck Squamous Cell Carcinoma Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 46 Middle East & Africa Head and Neck Squamous Cell Carcinoma Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 47 Middle East & Africa Head and Neck Squamous Cell Carcinoma Market Value, By End-user , 2021-2030 (US$ Billion)

Table 48 Sanofi: Overview

Table 49 Sanofi: Product Portfolio

Table 50 Sanofi: Key Developments

Table 51 F. Hoffmann-La Roche Ltd.: Overview

Table 52 F. Hoffmann-La Roche Ltd.: Product Portfolio

Table 53 F. Hoffmann-La Roche Ltd.: Key Developments

Table 54 Boehringer Ingelheim International GmbH.: Overview

Table 55 Boehringer Ingelheim International GmbH.: Product Portfolio

Table 56 Boehringer Ingelheim International GmbH.: Key Developments

Table 57 GSK plc : Overview

Table 58 GSK plc : Product Portfolio

Table 59 GSK plc : Key Developments

Table 60 Novartis AG : Overview

Table 61 Novartis AG : Product Portfolio

Table 62 Novartis AG : Key Developments

Table 63 Bayer AG : Overview

Table 64 Bayer AG : Product Portfolio

Table 65 Bayer AG : Key Developments

Table 66 Merck & Co., Inc. : Overview

Table 67 Merck & Co., Inc. : Product Portfolio

Table 68 Merck & Co., Inc. : Key Developments

Table 69 AstraZeneca : Overview

Table 70 AstraZeneca : Product Portfolio

Table 71 AstraZeneca : Key Developments

Table 72 Eli Lilly and Co : Overview

Table 73 Eli Lilly and Co : Product Portfolio

Table 74 Eli Lilly and Co : Key Developments

Table 75 Cipla Inc. : Overview

Table 76 Cipla Inc. : Product Portfolio

Table 77 Cipla Inc. : Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Head and Neck Squamous Cell Carcinoma Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Head and Neck Squamous Cell Carcinoma Market Share, By Drug Class, 2022 & 2030 (%)

Figure 4 Global Head and Neck Squamous Cell Carcinoma Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Head and Neck Squamous Cell Carcinoma Market Share, By Treatment, 2022 & 2030 (%)

Figure 6 Global Head and Neck Squamous Cell Carcinoma Market Share, By End-user , 2022 & 2030 (%)

Figure 7 Global Head and Neck Squamous Cell Carcinoma Market Share, By Region, 2022 & 2030 (%)

Figure 8 Global Head and Neck Squamous Cell Carcinoma Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 9 Salivary Gland Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 10 Oral and Oropharyngeal Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 11 Nasal Cavity &Paranasal Sinuses Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 12 Nasopharyngeal Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 13 Laryngeal Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 14 Hypo Pharyngeal Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 15 Global Head and Neck Squamous Cell Carcinoma Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 16 EGFR Inhibitors Drug Class in Global Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 17 Immune Checkpoint Inhibitors Drug Class in Global Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 18 Others Drug Class in Global Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 19 Global Head and Neck Squamous Cell Carcinoma Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 20 Intravenous Route of Administration in Global Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 21 Oral Route of Administration in Global Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 22 Others Route of Administration in Global Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 23 Global Head and Neck Squamous Cell Carcinoma Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 24 Radiation Treatment in Global Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 25 Chemotherapy Treatment in Global Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 26 Immunotherapy Treatment in Global Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 27 Global Head and Neck Squamous Cell Carcinoma Market Y-o-Y Growth, By End-user , 2022-2030 (%)

Figure 28 Hospitals End-user in Global Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 29 Specialty Clinics End-user in Global Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 30 Ambulatory Surgical Centers End-user in Global Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 31 Global Head and Neck Squamous Cell Carcinoma Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 32 North America Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 33 Asia-Pacific Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 34 Europe Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 35 South America Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 36 Middle East and Africa Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 37 North America Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 38 North America Head and Neck Squamous Cell Carcinoma Market Share, By Type, 2022 & 2030 (%)

Figure 39 North America Head and Neck Squamous Cell Carcinoma Market Share, By Drug Class, 2022 & 2030 (%)

Figure 40 North America Head and Neck Squamous Cell Carcinoma Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 41 North America Head and Neck Squamous Cell Carcinoma Market Share, By Treatment, 2022 & 2030 (%)

Figure 42 North America Head and Neck Squamous Cell Carcinoma Market Share, By End-user , 2022 & 2030 (%)

Figure 43 North America Head and Neck Squamous Cell Carcinoma Market Share, By Country, 2022 & 2030 (%)

Figure 44 South America Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 45 South America Head and Neck Squamous Cell Carcinoma Market Share, By Type, 2022 & 2030 (%)

Figure 46 South America Head and Neck Squamous Cell Carcinoma Market Share, By Drug Class, 2022 & 2030 (%)

Figure 47 South America Head and Neck Squamous Cell Carcinoma Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 48 South America Head and Neck Squamous Cell Carcinoma Market Share, By Treatment, 2022 & 2030 (%)

Figure 49 South America Head and Neck Squamous Cell Carcinoma Market Share, By End-user , 2022 & 2030 (%)

Figure 50 South America Head and Neck Squamous Cell Carcinoma Market Share, By Country, 2022 & 2030 (%)

Figure 51 Europe Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 52 Europe Head and Neck Squamous Cell Carcinoma Market Share, By Type, 2022 & 2030 (%)

Figure 53 Europe Head and Neck Squamous Cell Carcinoma Market Share, By Drug Class, 2022 & 2030 (%)

Figure 54 Europe Head and Neck Squamous Cell Carcinoma Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 55 Europe Head and Neck Squamous Cell Carcinoma Market Share, By Treatment, 2022 & 2030 (%)

Figure 56 Europe Head and Neck Squamous Cell Carcinoma Market Share, By End-user , 2022 & 2030 (%)

Figure 57 Europe Head and Neck Squamous Cell Carcinoma Market Share, By Country, 2022 & 2030 (%)

Figure 58 Asia-Pacific Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 59 Asia-Pacific Head and Neck Squamous Cell Carcinoma Market Share, By Type, 2022 & 2030 (%)

Figure 60 Asia-Pacific Head and Neck Squamous Cell Carcinoma Market Share, By Drug Class, 2022 & 2030 (%)

Figure 61 Asia-Pacific Head and Neck Squamous Cell Carcinoma Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 62 Asia-Pacific Head and Neck Squamous Cell Carcinoma Market Share, By Treatment, 2022 & 2030 (%)

Figure 63 Asia-Pacific Head and Neck Squamous Cell Carcinoma Market Share, By End-user , 2022 & 2030 (%)

Figure 64 Asia-Pacific Head and Neck Squamous Cell Carcinoma Market Share, By Country, 2022 & 2030 (%)

Figure 65 Middle East & Africa Head and Neck Squamous Cell Carcinoma Market Value, 2021-2030 (US$ Billion)

Figure 66 Middle East & Africa Head and Neck Squamous Cell Carcinoma Market Share, By Type, 2022 & 2030 (%)

Figure 67 Middle East & Africa Head and Neck Squamous Cell Carcinoma Market Share, By Drug Class, 2022 & 2030 (%)

Figure 68 Middle East & Africa Head and Neck Squamous Cell Carcinoma Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 69 Middle East & Africa Head and Neck Squamous Cell Carcinoma Market Share, By Treatment, 2022 & 2030 (%)

Figure 70 Middle East & Africa Head and Neck Squamous Cell Carcinoma Market Share, By End-user , 2022 & 2030 (%)

Figure 71 Sanofi: Financials

Figure 72 F. Hoffmann-La Roche Ltd.: Financials

Figure 73 Boehringer Ingelheim International GmbH.: Financials

Figure 74 GSK plc : Financials

Figure 75 Novartis AG : Financials

Figure 76 Bayer AG : Financials

Figure 77 Merck & Co., Inc. : Financials

Figure 78 AstraZeneca : Financials

Figure 79 Eli Lilly and Co : Financials

Figure 80 Cipla Inc. : Financials

세계 두경부 편평세포암 시장 – 2023-2030

Global Head and Neck Squamous Cell Carcinoma Market - 2023-2030